You are here:

Forthcoming Submission: crizotinib (Xalkori)

Indication: Treatment of adults with ROS1-positive advanced non-small cell lung cancer.

Drug Details

Drug Name: crizotinib (Xalkori)
Drug Manufacturer: Pfizer Ltd
BNF Category:
Submission type: Full submission
Patient Interest Group
Submission Deadline:
5/03/2018
SMC Meeting Date: Q2 2018
Advice Due: Q2 2018

Back